Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsTasha Nicholle SIMS, Bo GAO, Israel LOWY
Estimating the term…
The present invention provides methods for treating metastatic cancer comprising identifying subjects who will respond favorably to anti-VEGF therapy. According to certain aspects of the invention, subjects are identified based on their expression level of one or more predictive biomarkers. Favorable response to anti-VEGF therapy is indicated by high expression levels of certain biomarkers or by low expression levels of certain biomarkers. An exemplary predictive biomarker is VEGF-A. Also disclosed herein are prognostic biomarkers useful for identifying cancer-bearing subjects who are expected to have better relative survival outcomes.
A method for treating metastatic colorectal cancer (mCRC), the method comprising administering a VEGF antagonist to a patient, wherein the patient has been diagnosed with mCRC and has been selected for treatment with the VEGF antagonist on the basis of exhibiting elevated expression of VEGF-A;
A method for identifying a patient with metastatic colorectal cancer (mCRC) who is likely to respond favorably to anti-VEGF therapy, the method comprising obtaining a sample from the patient and measuring in the sample the level of VEGF-A;
Dependencies are inferred from the claim text.